Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2002

View Archived Issues

Malaria vaccine produced in milk of transgenic animals protective in monkeys

Mechanism of hypoglycemic effect of Acrp30 examined in mice

Airways-selective potassium channel opener in development by Novartis for asthma Rx

NVP-ABE-171: a PDE4 inhibitor with better activity than Ariflo in rodent models of lung inflammation

Vertex updates its progress and plans for 2002

INGN-201 does not integrate into the host cell genome, demonstrates activity as anticancer vaccine

INGN-251 endowed with both cell-killing and antimetastatic properties according to recent data

Encouraging phase Ia results of XTL-002 in hepatitis C

Peptor to begin phase II trial of DiaPep277 in treatment of LADA

4SC and Wilex enter research collaboration for second-generation uPA inhibitors

Disappointing results from phase III trial of SnET2 in wet AMD

Amerimmune initiates phase Ib study of Cytolin in HIV patients

Positive preliminary results from Corixa's phase III trial of RC-529 adjuvant

Pfizer discovers endothelin receptor antagonists selective for ETA subtype

Indole-based inhibitors of angiogenesis designed at Abbott

Grelan researchers identify benzothiazole COX-2 inhibitors useful for inflammation

Selective alpha1A-adrenoceptor antagonists claimed for therapy of BPH

New compounds from Lilly useful for treatment of conditions associated with glutamate hypofunction

Pharmacia presents protein kinase inhibitors and their potential uses in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...